


CERTIFICATE OF ELECTRONIC FILING

This correspondence is being filed with the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, via electronic filing, on the date below:

October 3, 2006

Date



Sharon V. Hart

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Rolf A. Brekken

Serial No.: 10/738,404

Filing Date: December 17, 2003

For: SELECTIVE ANTI-VEGF ANTIBODY
PRODRUG METHODS (As Amended)

Group Art Unit: 1642

Examiner: Joyce, C.

Atty. Dkt. No.: 3999.002587

**APPLICANTS' STATEMENT OF
THE SUBSTANCE OF THE INTERVIEW**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

The present document is Applicants' Statement of the Substance of the Interview, filed in response to the Examiner's Interview Summary dated September 19, 2006. Applicants agree with the Examiner's Interview Summary.

The present document is being filed within one month of the Examiner's Interview Summary and is therefore timely. Applicants' statement regarding the interview could not have been included with the response to the outstanding Official Action, as the response had already been filed. In this regard, a short telephone interview was requested in a telephone message from Applicants' representative on September 11, 2006. The response was filed in the morning of September 13, 2006, before the examiner called to conduct the interview.

In addition to discussing claim 10, which is free from rejection on the basis of prior art, Applicants also commented that claim 47 was free from rejection on the basis of prior art and enablement, and that the response had been filed taking note of the treatment of both claim 10 and claim 47.

Examiner Joyce kindly agreed to telephone Applicants' representative again should any issues remain after review of Applicants' response, with a view to resolving any remaining matters as efficiently as possible.

The present document does not constitute submission of a supplemental reply under 37 C.F.R. § 1.704(c)(8) (this document is instead being filed in response to a supplemental paper from the Office). The Office is not required to restart consideration of the response that has already been filed.

No fees are required in connection with the present document. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, please deduct such fees from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.003087.

Respectfully submitted,

PEREGRINE PHARMACEUTICALS, INC.
Customer No. 000052101



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

5353 W. Alabama, Suite 306
Houston, Texas, 77056
(713) 439-0108

Date: October 3, 2006